Moreover, plasma p- tau shows larger fold change between symptomatic AD patients and controls compared with plasma Aβ42/Aβ40, which leads to high test-retest reproducibility and robustness, supporting utility in clinical laboratory practice [38▪,48▪▪]. The gene discussed is MAPT; the disease is Alzheimer disease.